|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ISG15 |
Gene summary for ISG15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ISG15 | Gene ID | 9636 |
| Gene name | ISG15 ubiquitin like modifier | |
| Gene Alias | G1P2 | |
| Cytomap | 1p36.33 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | P05161 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9636 | ISG15 | GSM4909281 | Human | Breast | IDC | 1.76e-50 | 9.58e-01 | 0.21 |
| 9636 | ISG15 | GSM4909285 | Human | Breast | IDC | 1.02e-13 | 5.85e-01 | 0.21 |
| 9636 | ISG15 | GSM4909286 | Human | Breast | IDC | 2.74e-03 | -1.84e-01 | 0.1081 |
| 9636 | ISG15 | GSM4909287 | Human | Breast | IDC | 5.25e-14 | 6.08e-01 | 0.2057 |
| 9636 | ISG15 | GSM4909288 | Human | Breast | IDC | 2.15e-15 | 1.01e+00 | 0.0988 |
| 9636 | ISG15 | GSM4909290 | Human | Breast | IDC | 1.22e-09 | 5.22e-01 | 0.2096 |
| 9636 | ISG15 | GSM4909294 | Human | Breast | IDC | 3.33e-03 | 3.21e-01 | 0.2022 |
| 9636 | ISG15 | GSM4909297 | Human | Breast | IDC | 1.09e-07 | 2.77e-01 | 0.1517 |
| 9636 | ISG15 | GSM4909301 | Human | Breast | IDC | 2.89e-05 | 2.90e-01 | 0.1577 |
| 9636 | ISG15 | GSM4909304 | Human | Breast | IDC | 4.02e-03 | 2.61e-01 | 0.1636 |
| 9636 | ISG15 | GSM4909307 | Human | Breast | IDC | 3.39e-68 | 1.26e+00 | 0.1569 |
| 9636 | ISG15 | GSM4909308 | Human | Breast | IDC | 7.77e-81 | 1.38e+00 | 0.158 |
| 9636 | ISG15 | GSM4909309 | Human | Breast | IDC | 6.18e-38 | 1.10e+00 | 0.0483 |
| 9636 | ISG15 | GSM4909311 | Human | Breast | IDC | 8.44e-05 | -1.49e-01 | 0.1534 |
| 9636 | ISG15 | GSM4909312 | Human | Breast | IDC | 9.54e-03 | -1.54e-01 | 0.1552 |
| 9636 | ISG15 | GSM4909315 | Human | Breast | IDC | 1.17e-07 | 3.60e-01 | 0.21 |
| 9636 | ISG15 | GSM4909317 | Human | Breast | IDC | 3.66e-18 | 6.46e-01 | 0.1355 |
| 9636 | ISG15 | GSM4909318 | Human | Breast | IDC | 1.25e-06 | 7.90e-01 | 0.2031 |
| 9636 | ISG15 | GSM4909319 | Human | Breast | IDC | 1.10e-11 | 1.07e-01 | 0.1563 |
| 9636 | ISG15 | GSM4909320 | Human | Breast | IDC | 4.15e-15 | 9.17e-01 | 0.1575 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004564614 | Cervix | HSIL_HPV | regulation of erythrocyte differentiation | 7/737 | 47/18723 | 2.27e-03 | 2.28e-02 | 7 |
| GO:003210211 | Cervix | HSIL_HPV | negative regulation of response to external stimulus | 29/737 | 420/18723 | 2.53e-03 | 2.48e-02 | 29 |
| GO:004887215 | Cervix | HSIL_HPV | homeostasis of number of cells | 21/737 | 272/18723 | 2.64e-03 | 2.54e-02 | 21 |
| GO:000283111 | Cervix | HSIL_HPV | regulation of response to biotic stimulus | 24/737 | 327/18723 | 2.65e-03 | 2.55e-02 | 24 |
| GO:0032609 | Cervix | HSIL_HPV | interferon-gamma production | 11/737 | 112/18723 | 4.65e-03 | 3.87e-02 | 11 |
| GO:0032649 | Cervix | HSIL_HPV | regulation of interferon-gamma production | 11/737 | 112/18723 | 4.65e-03 | 3.87e-02 | 11 |
| GO:0060759 | Cervix | HSIL_HPV | regulation of response to cytokine stimulus | 14/737 | 162/18723 | 4.88e-03 | 4.02e-02 | 14 |
| GO:004507111 | Cervix | HSIL_HPV | negative regulation of viral genome replication | 7/737 | 56/18723 | 6.17e-03 | 4.81e-02 | 7 |
| GO:0001959 | Cervix | HSIL_HPV | regulation of cytokine-mediated signaling pathway | 13/737 | 150/18723 | 6.39e-03 | 4.96e-02 | 13 |
| GO:000181922 | Cervix | N_HPV | positive regulation of cytokine production | 38/534 | 467/18723 | 7.18e-09 | 1.58e-06 | 38 |
| GO:003139625 | Cervix | N_HPV | regulation of protein ubiquitination | 24/534 | 210/18723 | 8.06e-09 | 1.60e-06 | 24 |
| GO:003009925 | Cervix | N_HPV | myeloid cell differentiation | 33/534 | 381/18723 | 1.61e-08 | 2.52e-06 | 33 |
| GO:190332025 | Cervix | N_HPV | regulation of protein modification by small protein conjugation or removal | 25/534 | 242/18723 | 3.05e-08 | 3.66e-06 | 25 |
| GO:001922121 | Cervix | N_HPV | cytokine-mediated signaling pathway | 36/534 | 472/18723 | 9.30e-08 | 9.21e-06 | 36 |
| GO:001603225 | Cervix | N_HPV | viral process | 33/534 | 415/18723 | 1.23e-07 | 1.15e-05 | 33 |
| GO:003139725 | Cervix | N_HPV | negative regulation of protein ubiquitination | 13/534 | 83/18723 | 6.09e-07 | 3.75e-05 | 13 |
| GO:004563723 | Cervix | N_HPV | regulation of myeloid cell differentiation | 21/534 | 210/18723 | 6.68e-07 | 4.00e-05 | 21 |
| GO:190370623 | Cervix | N_HPV | regulation of hemopoiesis | 29/534 | 367/18723 | 8.22e-07 | 4.74e-05 | 29 |
| GO:004274211 | Cervix | N_HPV | defense response to bacterium | 28/534 | 350/18723 | 9.96e-07 | 5.53e-05 | 28 |
| GO:000268322 | Cervix | N_HPV | negative regulation of immune system process | 32/534 | 434/18723 | 1.02e-06 | 5.61e-05 | 32 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0516932 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0516941 | Breast | DCIS | Epstein-Barr virus infection | 46/846 | 202/8465 | 5.60e-08 | 1.13e-06 | 8.33e-07 | 46 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0516951 | Breast | DCIS | Epstein-Barr virus infection | 46/846 | 202/8465 | 5.60e-08 | 1.13e-06 | 8.33e-07 | 46 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
| hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa05169110 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
| hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0516923 | Cervix | HSIL_HPV | Epstein-Barr virus infection | 22/459 | 202/8465 | 1.35e-03 | 9.68e-03 | 7.82e-03 | 22 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ISG15 | SNV | Missense_Mutation | rs752866829 | c.109N>A | p.Gly37Ser | p.G37S | P05161 | protein_coding | deleterious(0.04) | benign(0.283) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ISG15 | SNV | Missense_Mutation | c.131N>T | p.Arg44Leu | p.R44L | P05161 | protein_coding | tolerated(0.06) | benign(0.123) | TCGA-D5-6920-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ISG15 | SNV | Missense_Mutation | rs368865539 | c.275N>A | p.Arg92His | p.R92H | P05161 | protein_coding | tolerated(0.13) | benign(0.115) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ISG15 | SNV | Missense_Mutation | c.178N>A | p.Leu60Ile | p.L60I | P05161 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-BS-A0UL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ISG15 | SNV | Missense_Mutation | rs148041041 | c.131N>A | p.Arg44His | p.R44H | P05161 | protein_coding | tolerated(0.1) | probably_damaging(0.952) | TCGA-EC-A24G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| ISG15 | deletion | Frame_Shift_Del | novel | c.411delN | p.Glu139SerfsTer7 | p.E139Sfs*7 | P05161 | protein_coding | TCGA-SL-A6JA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ISG15 | SNV | Missense_Mutation | novel | c.464G>T | p.Arg155Leu | p.R155L | P05161 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-55-6981-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | chemo | CR |
| ISG15 | SNV | Missense_Mutation | rs748078443 | c.202G>A | p.Gly68Ser | p.G68S | P05161 | protein_coding | tolerated(0.14) | possibly_damaging(0.588) | TCGA-34-5928-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9636 | ISG15 | ENZYME, DRUGGABLE GENOME | inhibitor | IRINOTECAN | IRINOTECAN |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |